Lindy Goddard

1.1k total citations
22 papers, 927 citations indexed

About

Lindy Goddard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lindy Goddard has authored 22 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Lindy Goddard's work include Prostate Cancer Treatment and Research (11 papers), HER2/EGFR in Cancer Research (8 papers) and Prostate Cancer Diagnosis and Treatment (5 papers). Lindy Goddard is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), HER2/EGFR in Cancer Research (8 papers) and Prostate Cancer Diagnosis and Treatment (5 papers). Lindy Goddard collaborates with scholars based in United Kingdom, Italy and Austria. Lindy Goddard's co-authors include M. E. Harper, E Glynne-Jones, K. Griffiths, Julia M.W. Gee, Robert I. Nicholson, Stephen Hiscox, Denise Barrow, W.B. Peeling, A. E. Wakeling and Helen E. Jones and has published in prestigious journals such as Cancer Research, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

Lindy Goddard

20 papers receiving 897 citations

Peers

Lindy Goddard

PRM

ONCOL

EDM

John T. Isaacs United States

Shi Chang United States

Marileila Varella‐Garcia United States

Debra M. Sutkowski United States

Nobuo Ochi Japan

Mikinori Sato Japan

Liyan Xue China

Whitney Banach‐Petrosky United States

Alexandra Eyzaguirre United States

Shohreh Varmeh United States

John T. Isaacs United States

Lindy Goddard

550 ×1.1

443 ×1.0

PRM

213 ×0.6

ONCOL

172 ×0.9

128 ×1.1

EDM

Citations per year, relative to Lindy Goddard Lindy Goddard (= 1×) peers John T. Isaacs

Countries citing papers authored by Lindy Goddard

Since Specialization

Citations

This map shows the geographic impact of Lindy Goddard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindy Goddard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindy Goddard more than expected).

Fields of papers citing papers by Lindy Goddard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindy Goddard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindy Goddard. The network helps show where Lindy Goddard may publish in the future.

Co-authorship network of co-authors of Lindy Goddard

This figure shows the co-authorship network connecting the top 25 collaborators of Lindy Goddard. A scholar is included among the top collaborators of Lindy Goddard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindy Goddard. Lindy Goddard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gee, Julia M.W., Mei Meng, Richard A. McClelland, et al.. (2015). Abstract P3-05-19: A new cell panel to study oestrogen receptor loss in acquired endocrine resistant breast cancer. Cancer Research. 75(9_Supplement). P3–5. 1 indexed citations

Smith, Christopher R., Lindy Goddard, Nicola Jordan, et al.. (2013). Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine Related Cancer. 20(5). 691–704. 31 indexed citations

Hiscox, Stephen, Christopher R. Smith, Lindy Goddard, et al.. (2012). Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer. 12(1). 458–458. 62 indexed citations

Gee, Julia M.W., Robert I. Nicholson, Denise Barrow, et al.. (2011). Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation. 5(2). 67–77. 6 indexed citations

Hutcheson, Iain R., Lindy Goddard, Denise Barrow, et al.. (2011). Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research. 13(2). R29–R29. 36 indexed citations

Goddard, Lindy, et al.. (2010). Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins. Breast Cancer Research. 12(S1). 5 indexed citations

Jones, Helen E., Lindy Goddard, Julia M.W. Gee, et al.. (2004). Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine Related Cancer. 11(4). 793–814. 244 indexed citations

Harper, M. E., Lindy Goddard, Christopher G. Smith, & Robert I. Nicholson. (2003). Characterization of a transplantable hormone‐responsive human prostatic cancer xenograft TEN12 and its androgen‐resistant sublines. The Prostate. 58(1). 13–22. 5 indexed citations

Jones, Helen, Lindy Goddard, Julia M.W. Gee, et al.. (2003). Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; IRESSA™) in DU 145 human prostate cancer cells. European Urology Supplements. 2(6). 7–7.

10.

Harper, M. E., Lindy Goddard, Jean W. Assender, et al.. (2002). Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor. The Prostate. 52(1). 59–68. 17 indexed citations

11.

Jones, Helen, Denise Barrow, Carol M. Dutkowski, et al.. (2001). Effect of an EGF‐R selective tyrosine kinase inhibitor and an anti‐androgen on LNCaP cells: Identification of divergent growth regulatory pathways. The Prostate. 49(1). 38–47. 14 indexed citations

12.

Harper, M. E., et al.. (1998). Expression of androgen receptor and growth factors in premalignant lesions of the prostate. The Journal of Pathology. 186(2). 169–177. 50 indexed citations

13.

Glynne-Jones, E, et al.. (1996). Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. British Journal of Cancer. 74(6). 910–916. 122 indexed citations

14.

Glynne-Jones, E, Lindy Goddard, & M. E. Harper. (1996). Comparative analysis of mrna and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Human Pathology. 27(7). 688–694. 58 indexed citations

15.

Harper, M. E., Lindy Goddard, E Glynne-Jones, W.B. Peeling, & K. Griffiths. (1995). Epidermal growth factor receptor expression by Northern analysis and immunohistochemistry in benign and malignant prostatic tumours. European Journal of Cancer. 31(9). 1492–1497. 18 indexed citations

16.

Hepburn, Peter J., et al.. (1995). Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. The Histochemical Journal. 27(3). 196–203. 24 indexed citations

17.

Hepburn, Peter J., et al.. (1995). Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. The Histochemical Journal. 27(3). 196–203. 29 indexed citations

18.

Harper, M. E., Lindy Goddard, E Glynne-Jones, et al.. (1993). An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors. The Prostate. 23(1). 9–23. 61 indexed citations

19.

Harper, M. E., E Glynne-Jones, Lindy Goddard, et al.. (1992). Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. The Prostate. 20(3). 243–253. 63 indexed citations

20.

Harper, M. E., Lindy Goddard, Douglas W. Wilson, et al.. (1992). Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinoma. The Prostate. 21(1). 75–84. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact